Stock Ratings / Health Care / AEMD / options

NMTC (33) PLSM (47) FEMY (30) ICU (31) ⌘ Pro Terminal →

Aethlon Medical Inc. (AEMD) Options Positioning, Max Pain & Unusual Sweeps

$5.44 -1.45% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $5.42

Aethlon Medical Inc. (AEMD) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $8.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on AEMD Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is AEMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Aethlon Medical Inc. (NASDAQ: AEMD) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $5.44 (-1.45% 1D, market cap $8.9M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, AEMD ranks #594 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does AEMD compare to NMTC and PLSM in the Health Care sector?

▼

Within the Health Care sector (Medical/Dental Instruments), AEMD carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, NMTC (NeuroOne Medical Technologies Corporation) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $8.8M) and PLSM (Pulsenmore Ltd.) posts a D grade (47/100 RQD, P/E N/A, ROIC —, cap $10.5M). Among the 5-stock peer group, AEMD leads on earnings multiple (N/A) while AEMD leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for AEMD?

▼

Per AEMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-03-31, CIK 0000882291), Aethlon Medical Inc. generated $0 in revenue, -$7.2M in net income, and -$7.0M in free cash flow against $8.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $5.42 (-0.45%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.8% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AEMD)Realized 20D OHLCV Swing Band: ±12.2%

Deterministic 5-Pillar Attribution (38/100 Composite)

🔍 WHY AEMD SCORES 38/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (26% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▲ #2 Bullish Driver: Whale & Options Positioning+9/20 pts (24% of score)

20D Institutional Volume Accumulation (±12.2% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$5.86-11.9% Next Q

Q2 (-2Q)

Grade D$5.16-0.2% Next Q

Q3 (-1Q)

Grade D$5.15+5.6% Next Q

Current

Grade D-$5.44-7.8% Hist 90D α

Trajectory: D (46) → D- (38)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a AEMD Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While AEMD currently carries a cautious 38/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.53) and Max Pain ($5.71) forces dealer call-delta covering toward $28.25.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $AEMD• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “AEMD Beats Next Quarter EPS Consensus (Dec 29, 2026) & Holds Above 200D SMA”

YES 38%NO 62%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.2%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (AEMD)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for AEMD.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring AEMD)

✓Walkthrough of AEMD's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

AEMD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -54.67%▼ DESCENDING CHANNEL

2026-11-02O $5.55H $5.55L $5.44C $5.44VOL 12.8K

RES: $6.87SUP: $0.25SMA50: $4.53SMA200: $7.74

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

AEMD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 AEMD Butterfly Map → + Track AEMD →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on AEMD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for AEMD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for AEMD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AEMD)

Health Care Rank #594 of 1016 ⚔️ NMTC vs AEMD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (AEMD vs. NMTC, PLSM, FEMY, ICU)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Aethlon Medical Inc. (AEMD) ranks #594 by composite RQD confidence (38/100, grade D-) and #904 by equity capitalization ($8.9M). Within this direct 5-issuer industry benchmark cohort, AEMD leads on earnings valuation at N/A trailing P/E, while AEMD leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. PLSM currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with AEMD at 38/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
AEMD ACTIVE Aethlon Medical Inc.	D-	38/100	—	—	-35.0%	-1.45%	$8.9M	Benchmark Subject
NMTC NeuroOne Medical Technologies Corporation	E	33/100	—	56.5%	-35.0%	-4.39%	$8.8M	/nmtc-vs-aemd →
PLSM Pulsenmore Ltd.	D	47/100	—	—	—	+3.09%	$10.5M	/plsm-vs-aemd →
FEMY Femasys Inc.	E	30/100	—	62.0%	-35.0%	+1.11%	$11.3M	/femy-vs-aemd →
ICU SeaStar Medical Holding Corporation	E	31/100	—	95.7%	-35.0%	-3.03%	$12.2M	/icu-vs-aemd →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2026-03-31 • CIK 0000882291

In its most recent audited fiscal period (FY2025, filed 2026-03-31), Aethlon Medical Inc. (AEMD) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$7.2M, operating cash flow of -$7.0M, and free cash flow of -$7.0M (+8.4% YoY). On the balance sheet, AEMD closed FY2025 with $8.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2026-03-31	$0	-$7.2M	-$7.0M	-$7.0M	$8.1M	—
FY2024 (FY)	2025-03-31	$0	-$13.4M	-$7.6M	-$7.6M	$6.5M	—
FY2023 (FY)	2024-03-31	$0	-$12.2M	-$10.1M	-$10.1M	—	—

3. AEMD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is AEMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does AEMD compare to NMTC and PLSM in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for AEMD?

Where is AEMD trading relative to its 50-day, 200-day, and 52-week technical levels?

AEMD last traded at $5.44 (-1.45% on volume of 27,685 shares), positioning the stock +20.09% above its 50-day simple moving average ($4.53) and -29.72% below its 200-day simple moving average ($7.74). Across its 52-week range of $1.41 to $26.90, AEMD sits at the 15.8% percentile with a 14-day RSI of 55.0 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.2% ($4.78 to $6.10).

AEMD Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is AEMD's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for AEMD.

Direct Sub-Reports: AEMD RQD Cockpit AEMD 12M Forecast AEMD Earnings & Move AEMD Dividends & DRIP AEMD Insiders & 13F AEMD Whale Options AEMD Profit Sankey AEMD News & Why

Sector Peer Dials

Compare →

NMTC E

NeuroOne Medical Technologies Corporation

SeaStar Medical Holding Corporation

Intelligent Bio Solutions Inc.

29 /100

AEMD Core Snapshot

Market Cap $8.9M

Trailing / Fwd P/E — / —

Gross Profit Margin —

Return on Capital (ROIC) -35.0%

Free Cash Flow Yield —

12M Base Price Target $4.95

FREE TRADER TOOLS

Own AEMD Alongside Other Stocks? Run a 30-Second Crash X-Ray

Drop 3–5 tickers into our live Portfolio X-Ray to spot hidden accounting time-bombs and see your composite RQD dial.

⚡ X-Ray My Portfolio With AEMD → 🏆 Trade AEMD in $100K Prop Arena →

AEMD Wire

Why It Moved →

Direct Company Event TradingView • 2h ago

Aethlon Medical, Inc. Estimates – NASDAQ:AEMD

Direct Company Event Yahoo Finance UK • 5h ago

Aethlon Medical, Inc. (AEMD) Seasonal returns chart

Direct Company Event Stock Titan • 8h ago

Two Jane Street subsidiaries report stakes in Aethlon Medical (AEMD).

Peer / Ecosystem Wire Investing.com India • 11h ago

Form 4 Aethlon Medical Inc: Angela Rossetti (Director) For: 17 April By Investing.com

Peer / Ecosystem Wire Investing.com UK • 14h ago

Form 4 Aethlon Medical Inc: Edward G. Broenniman (Director) For: 30 September

ROARABLE RATING BRIEF • RQD 38/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

AEMD — Aethlon Medical Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:52:09Z

Roarable Rating Brief: What This Means to a Prospective Investor

The Roarable RQD score is 38 out of 100, a letter grade of D-, with the verdict "Roarable Sell — Vulnerable Balance Sheet & Flow" (per the Roarable RQD rating). Across its five pillars:

Fundamental Cash Engine: 5 / 20. Per the Roarable RQD rating, this reflects ROIC of -35% and an FCF yield of 0%. For an investor, this means the business is not currently generating returns on capital or free cash flow; valuation cannot rest on earnings or cash yield.
Whale 13F Flow: 9 / 20. Per the Roarable RQD rating, this pillar covers institutional accumulation and options positioning. The score is below midpoint, so institutional support signals are weak in the source data.
Insider Conviction: 5 / 20. Per the Roarable RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. A low score indicates insider activity does not provide a strong conviction signal.
Macro Regime Fit: 9 / 20. Per the Roarable RQD rating, beta is 1.0 with sector sensitivity considered. A neutral beta combined with a low score means the stock offers no clear macro tailwind in the framework.
Forensic Balance Sheet: 10 / 20. Per the Roarable RQD rating, Altman Z is 2.5, Piotroski F is 3/9, and Debt/Equity is 0.5. This is the strongest pillar, but still sub-50%, indicating balance-sheet fragility.

Investor implications: the upside case depends on a turnaround in operating cash generation, which the current data does not show. The valuation tradeoff is that the stock trades at a $8.9M market capitalization with negative ROIC, so price action is not anchored by reported earnings. The low pillar scores in cash engine, flow, and insider conviction point to limited near-term confirmation for a recovery thesis. This is an analytical summary, not personalized advice.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$0.0M	$-7.3M	$-7.2M	N/A	$-7.0M	$7.0M	N/A
FY 2024	$0.0M	$-9.3M	$-13.4M	N/A	$-7.6M	$4.8M	N/A
FY 2023	$0.0M	$-12.6M	$-12.2M	N/A	$-10.1M	N/A	N/A

Per the SEC financials, the company reported no revenue and operating losses in each period shown, with gross, operating, and net margins all at 0% per the market data. Per the market data, ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 3/9, with Debt/Equity of 0.5. Cash reported at $7.0M for FY 2025 compared with $4.8M for FY 2024, while operating losses narrowed from $-9.3M to $-7.3M over that span.

Open Questions

What specific products or revenue streams, if any, generate the company's income given $0.0M reported revenue?
What is the cash runway implied by FY 2025 cash of $7.0M against operating losses of $-7.3M?
What are the terms, size, and direction of the Form 4 transactions and the Jane Street subsidiary stake disclosures?
Why do market-cap figures differ between the profile ($0.0B) and market data ($8.9M), and which is correct?
What is the debt structure behind the reported Debt/Equity of 0.5 when debt is listed as N/A in every period?

AEMD Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Aethlon Medical Inc. (AEMD) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to AEMD Debate Forum (3) ↓

🟡 MARKET WIRE TradingView • 2h ago

Aethlon Medical, Inc. Estimates – NASDAQ:AEMD

TradingView report covering Aethlon Medical Inc. (AEMD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance UK • 5h ago

Aethlon Medical, Inc. (AEMD) Seasonal returns chart

Yahoo Finance UK report covering Aethlon Medical Inc. (AEMD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 8h ago

Two Jane Street subsidiaries report stakes in Aethlon Medical (AEMD).

Stock Titan report covering Aethlon Medical Inc. (AEMD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com India • 11h ago

Form 4 Aethlon Medical Inc: Angela Rossetti (Director) For: 17 April By Investing.com

Investing.com India report covering Aethlon Medical Inc. (AEMD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com UK • 14h ago

Form 4 Aethlon Medical Inc: Edward G. Broenniman (Director) For: 30 September

Investing.com UK report covering Aethlon Medical Inc. (AEMD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 17h ago

Aethlon Medical (AEMD) Edges Up 0.19% to $5.16, Sitting Midway Between Support and Resistance - RVOL Spike

https://www.siam.in/ report covering Aethlon Medical Inc. (AEMD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH https://www.dars.gov.et/ • 20h ago

AEMD Q3 2026 Earnings: Loss Per Share Misses Consensus by a Wide Margin - Diluted EPS Report

https://www.dars.gov.et/ report covering Aethlon Medical Inc. (AEMD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH https://www.dars.gov.et/ • 23h ago

AEMD Q3 2026 Earnings: Wider-Than-Expected Loss With No Revenue Figure Provided - Revenue Miss Report

https://www.dars.gov.et/ report covering Aethlon Medical Inc. (AEMD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

AEMD Bull vs. Bear Conversation Board — What's Your Call at $5.44?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON AEMD 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $4.86 (-12.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is AEMD (D- • RQD 38/100) a Buy at $5.52?

Welcome to the AEMD (Aethlon Medical Inc.) Roar Pit. Current RQD Composite is 38/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Medical/Dental Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $4.20 (-23.9%)

Spot @ $5.52

Pump the brakes on AEMD — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on AEMD, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Aethlon Medical Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

QU QuantViper Verified K Arena Trader 🐂 BULLISH 🎯 Target: $6.46 (+17.0%)

Spot @ $5.52

AEMD cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on AEMD, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $5.52 (52-wk range $1.41 - $26.90), any beat on forward guidance forces shorts and underweight funds to chase.